Tocilizumab treatment in critical COVID-19: Report from a hospital center [Brief]

Keywords: COVID-19, Respiratory Distress Syndrome, Tocilizumab, SARS-CoV-2, Monoclonal antibodies, Perú

Abstract

A descriptive study was carried out, in which clinical and laboratory characteristics were evaluated in patients with a diagnosis of acute respiratory distress syndrome (ARDS) secondary to SARS-CoV-2 infection and who received Tocilizumab. Twentyfour patients received Tocilizumab, the majority were male (95.8%), the most frequent comorbidity was obesity (33.3%). At the time of receiving Tocilizumab the median PAO2 / FiO2 was 159.5 (IQR 114.5-255, 3). Twenty-one (87.5%) patients presented clinical improvement and 3 (12.5%) died. Fifteen patients (62.5%) developed hepatotoxicity, the majority grade 3 (33.3%) and three (12.5%) patients presented grade 4 liver injury. Eleven patients (45.8%) presented bacterial superinfection, the more common organism being Acinetobacter baumannii. After the administration of Tocilizumab, more than half of the patients presented an adverse reaction; despite this, mortality was low, and the majority had a clinical improvement.

Downloads

Download data is not yet available.
Published
2021-08-19
How to Cite
1.
Hueda Zavaleta M, Bardales Silva F, Copaja Corzo C, Flores Palacios R, Barreto Rocchetti L, Córdova Tejada E. Tocilizumab treatment in critical COVID-19: Report from a hospital center [Brief]. Acta Med Peru [Internet]. 2021Aug.19 [cited 2021Sep.18];38(2). Available from: https://amp.cmp.org.pe/index.php/AMP/article/view/1919
Section
ORIGINAL ARTICLES